177Lu-FAP-2286 (177Lu-3BP-2286) is a molecule from the FAPi family developed by the German company 3B-Pharma and which rights (world except Europe) were acquired by Clovis Oncology in September 2019. The molecule is developed as a Theranostic pair with the diagnostic counterpart labeled with 68Ga.

The drug is based on a Fibroplast Activation Protein (FAP)-specific enzyme inhibitor (FAPi). FAPis targets cancer-associated fibroblasts, which is apparently relevant as target in more than 90% of all solid tumors. Besides cancer, FAPis may also be used for benign diseases such as fibroses, artherosclerosis, rheumatoid arthritis, sarcoidosis, etc.

Target/Mechanism: FAPi

Leading Emitter: beta electrons (β)